Mostrar el registro sencillo

dc.contributor.authorRodrigo, Guilermo
dc.contributor.authorRuiz González, Raúl
dc.contributor.authorMontagud Martínez, Roser
dc.contributor.authorDorta Gorrín, Alexis
dc.contributor.authorPablo Marcos, Daniel
dc.contributor.authorGozalo Margüello, Mónica
dc.contributor.authorCalvo Montes, Jorge
dc.contributor.authorNavas Méndez, Jesús 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-05-02T11:08:40Z
dc.date.available2024-05-02T11:08:40Z
dc.date.issued2024-04-11
dc.identifier.issn2470-1343
dc.identifier.otherPDC2022-133941-I00es_ES
dc.identifier.urihttps://hdl.handle.net/10902/32719
dc.description.abstractGene sequencing in back of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is the current approach for discriminating infections produced by different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the clinic. However, sequencing is often a time-consuming step, which hinders the deployment of a very fast response during a pandemic. Here, we propose to run a CRISPR-Cas12a reaction after completing the RT-qPCR and in the very same pot to detect with high specificity genetic marks characterizing variants of concern. A crRNA was appropriately designed to detect the S gene of the SARS-CoV-2 Omicron BA.1 variant. A significant response with >20-fold dynamic range was obtained for the Omicron BA.1 S gene, while the Delta S gene did not produce any detectable signal. The sensitivity of the method was analyzed with a series of diluted samples and different Cas12a nucleases. A correlation between the RT-qPCR CT values and the CRISPR-Cas12a reaction signals was observed. Variant discrimination with the CRISPR-Cas12a reaction was possible in some minutes with high accuracy from patient samples. In conclusion, CRISPR-Cas systems seem ready to be exploited in the clinic to boost personalized diagnoses and accelerate epidemiological surveillance in a cost-effective way.es_ES
dc.description.sponsorshipWork supported by Generalitat Valenciana (GVA-COVID19/2021/036), Ministerio de Ciencia e Innovación (PDC2022−133941-I00; cofunded by NextGenerationEU), CRUE and Banco Santander (Fondo Supera Covid-19), CSIC PTI Salud Global (NextGenerationEU Fund, regulation 2020/2094), and IDIVAL (INNVAL21/13).es_ES
dc.format.extent5 p.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Chemical Societyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceACS Omega 2024, 9, 18046-18050es_ES
dc.subject.otherCRISPR diagnosticses_ES
dc.subject.otherInfectious diseasees_ES
dc.subject.otherVirus evolutiones_ES
dc.titleRapid and accurate detection of the SARS-CoV-2 omicron variant with a CRISPR-Cas12a reaction in the RT-qPCR Potes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PDC2022-133941-I00/ES/DESARROLLO DE UNA PLATAFORMA DE DIAGNOSTICO RAPIDO BASADA EN DESPLAZAMIENTO DE HEBRAS MEDIADO POR CRISPR-CAS9 PARA LA DETECCION MULTIPLEXADA DE ACIDOS NUCLEICOS/
dc.identifier.DOI10.1021/acsomega.3c09717
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International